Skip to content

Study of Hospitalised Patients With Acute Respiratory Conditions

Observational Cohort Study of Hospitalised Patients With Acute Respiratory Conditions

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05095090
Acronym
CHESTY
Enrollment
130
Registered
2021-10-27
Start date
2022-02-02
Completion date
2024-04-30
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Disease, Asthma, COPD Exacerbation Acute, Pneumonia

Keywords

Asthma, COPD (Chronic Obstructive Pulmonary Disease), Pneumonia, ILD (Interstitial Lung Diseases), Pulmonary Embolism, Pleural Diseases, Bronchiectasis

Brief summary

This observational study aim to characterise patients admitted to hospital with an acute respiratory condition, or acute worsening of their chronic lung condition. This will enable identification of predictors of future risk, as well as develop potential interventions targets.

Detailed description

This will be an observational cohort study, recruiting patients who have been admitted to hospital with an acute respiratory condition. This can include exacerbation of an existing chronic lung disease such as asthma, COPD, interstitial lung disease, bronchiectasis and pleural disease, or contracting an acute illness including pulmonary embolism, pneumonia, or any other respiratory infection. The patients will be screened and recruited whilst still hospitalised and followed up for one year after discharge. The participants will undergo a baseline study visit while in hospital, with the option to have further follow up visits (up to three occasions) in the following year to assess clinical recovery. The participants will be offered the choice to undertake the follow up assessments via any of the following routes: * a telephone consultation or * a face to face visit either in the Biomedical Research Centre (BRC) or * during a research visit from another ethically approved study or * during routine clinical follow up organised by the hospital clinical team. The participants can choose not to attend any further follow up visits after discharge. Any planned clinical follow-up arranged by the hospital team will occur according to clinical needs. If the participant is re-admitted during the 12 months after enrolment, assessments identical to the baseline visit can be repeated. A final remote visit will be carried out at 12 months post-discharge (+/- 1 month) to collect data about health care utilisation (e.g. hospitalisation rate, length of stay in hospital, death rate, antibiotic/steroid prescriptions) from both primary and secondary healthcare records. The participants are not required to attend this final visit as data will be collected remotely.

Interventions

None listed

Sponsors

University Hospitals, Leicester
CollaboratorOTHER
University of Leicester
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

Hospitalised Patients Inclusion Criteria: 1. Hospital admission with an acute respiratory diagnosis 2. Participant is willing & able to give informed consent for participation in the study 3. Aged 18 years or above 4. Able (in the Investigators opinion) & willing to comply with all study requirements

Exclusion criteria

1. Unstable or life-threatening cardiac disease including myocardial infarction or unstable angina during current admission. 2. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. 3. Known pregnancy Matched Controls Inclusion Criteria: 1. Aged 18 years or above 2. Patients with stable chronic respiratory conditions or healthy volunteers 3. Able (in the Investigators opinion) & willing to comply with all study requirements 7.3.2

Design outcomes

Primary

MeasureTime frameDescription
30 days mortality rate30 daysTo calculate the percentage of mortality within 30 days from consent
Length of index hospital admission stayVariable (up to 52 weeks)To calculate the length of the index hospital stay
30 days hospital re-admission rate30 daysTo calculate the percentage of readmission due to the same acute respiratory illness within 30 days from consent

Secondary

MeasureTime frameDescription
Time from consent to death (respiratory causes and all causes)52 weeksTo measure the time from consent to death within 52 weeks from consent. This will include both respiratory and all causes of mortality
Total number of hospital readmission due to same underlying chronic lung disease.52 weeksTo evaluate the number of hospital readmission episodes due to same underlying chronic lung disease over a 52 weeks period.
Total number of non-hospitalised exacerbations of underlying chronic lung disease52 weeksTo evaluate the number of non-hospitalised exacerbations of chronic lung disease e.g. asthma, Chronic Obstructive Pulmonary Diseases (COPD), etc. over 52 weeks

Other

MeasureTime frameDescription
Assessment of breathlessness using eMRC dyspnoea scale52 weeksTo evaluate the degree of breathlessness at baseline and following recovery from acute respiratory illness using Extended MRC dyspnoea scale(eMRC). eMRC dyspnoea scale ranges from 1 to 5b with higher score indicates worse outcomes.
Assessment of quality of Life/symptoms using St. George's Respiratory Questionnaire (SGRQ)52 weeksSt. George's Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026